LEXINGTON, Mass.--(BUSINESS WIRE)--Sep. 2, 2021--
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in the following investor conferences:
H.C. Wainwright 23rd Annual Global Investment Conference
Date: Monday, September 13, 2021
Time: Available On-Demand Beginning at 7:00 a.m. ET
Format: Analyst-Hosted Fireside Conversation
To view these events, please visit the Investors & Media page of the company’s website. After the presentations, the events will remain archived on the website for 90 days.
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics is a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases. Two of the company’s lead product candidates, reproxalap and ADX-629, target RASP, which are pre-cytokine, systems-based mediators of inflammation. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191 (methotrexate for intravitreal injection), a drug candidate in Phase 3 testing for the prevention of proliferative vitreoretinopathy. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005445/en/
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218
Investors & Media:
Sharon Merrill Associates, Inc.
Source: Aldeyra Therapeutics, Inc.